{"entity":{"id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ALK201 in advanced solid tumours, run by Shanghai Allink Biotherapeutics Co., Ltd., now recruiting.","summary":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06656390 by Shanghai Allink Biotherapeutics Co., Ltd., with 202 participants planned, started 2024-10-24 and due to reach its primary completion in 2027-10-22. Interventions recorded: ALK201.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06656390","url":"https://clinicaltrials.gov/study/NCT06656390"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06656390","phase":"1/2","setting":"A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","enrolled":202,"outcomes":[]},"route":"/trials/nct06656390/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}